Drugs / TAF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT07203118 | Jul 2025 → Jun 2027 expected | chronic hepatitis B virus infection | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07203118 ↗ |
| Route | Oral | “taken once daily with or within 30 minutes after a meal” NCT07203118 ↗ |